Genentech, the Roche Group’s fully owned U.S. subsidiary, has unveiled the Genentech Hillsboro Manufacturing Expansion, a plan to invest approximately $750 million in a new device fill-finish facility at its 75-acre campus in Hillsboro, Oregon. Announced from Basel, Switzerland on 20 August 2026, the project will roughly double the size of the existing site and add end-to-end device filling capabilities that support Roche and Genentech’s expanding pipeline of injectable medicines.
The scale of the commitment places the Genentech Hillsboro Manufacturing Expansion among the largest single-site pharmaceutical manufacturing investments the company has announced in the Pacific Northwest. Genentech said the new facility will handle the assembly of injectable medicines and delivery devices, extending the site’s role beyond its current operations and positioning Hillsboro as a hub for advanced drug-delivery technology within the broader Roche Group manufacturing network.
Genentech expects the buildout to create 250 high-wage manufacturing jobs once the facility reaches commercial operations, alongside roughly 200 construction jobs in Oregon during the development phase. Commercial operations at the expanded site are targeted to begin in 2031, giving the company a multi-year runway to complete construction, install equipment, and validate manufacturing lines ahead of regulatory inspection.
Company officials framed the investment as part of a longer-term strategy to strengthen domestic drug production capacity. The facility is designed for flexibility, meaning it can run both high-volume and low-volume device filling operations across a broad range of Roche and Genentech products, allowing the site to adapt as the companies’ therapeutic portfolio evolves over the coming decade.
Genentech Hillsboro Manufacturing Expansion Doubles Site Capacity for Injectable Devices
The Genentech Hillsboro Manufacturing Expansion centers on advanced drug delivery devices such as pre-filled syringes and autoinjectors, categories that have become increasingly central to how biologic medicines reach patients. These devices allow certain treatments to be administered outside a traditional hospital or infusion-center setting, a shift that can reduce the burden of care for patients managing chronic conditions.
By building dedicated capacity for these device formats, Genentech is signaling that self-administered and at-home treatment options will play a growing role in its future product launches. Pre-filled syringes and autoinjectors typically require specialized assembly lines that combine sterile drug filling with precision device engineering, a combination the Hillsboro facility has been designed to support at scale.
The flexible design behind the Genentech Hillsboro Manufacturing Expansion is intended to let the company respond quickly as its pipeline shifts between disease areas, including oncology, immunology, neurology, and ophthalmology, without requiring a separate manufacturing buildout for each new device format that reaches commercial approval. Because the line is engineered for both high- and low-volume runs, Genentech can direct capacity toward newly approved therapies without a lengthy retrofit process.
Genentech Hillsboro Manufacturing Expansion Follows Holly Springs Facility Topping Out
The Genentech Hillsboro Manufacturing Expansion follows the recent topping out of Genentech’s manufacturing facility in Holly Springs, North Carolina, a separate project strategically built to support global production of the company’s future portfolio of metabolic medicines, including next-generation obesity treatments. Together, the two facilities represent a coordinated push to expand Roche’s domestic manufacturing base across different therapeutic categories.
Roche and Genentech’s existing U.S. footprint already includes 13 manufacturing sites and 15 research and development sites, employing approximately 25,000 people across 24 locations in eight states. The Hillsboro and Holly Springs projects extend that footprint further and reinforce the company’s position as one of the larger pharmaceutical employers operating domestic production infrastructure in the United States.
The timing of the Genentech Hillsboro Manufacturing Expansion lands alongside a broader industry and regulatory push toward onshoring pharmaceutical production. U.S. regulators have introduced programs intended to streamline facility reviews and encourage domestic drug manufacturing construction, and large-scale commitments of this kind align with that policy direction, even though Genentech did not cite specific regulatory programs in its announcement.
Genentech Hillsboro Manufacturing Expansion Reflects Broader Roche US Investment Strategy
Roche, listed on the Swiss stock exchange under SIX: RO and ROP and traded in the U.S. over-the-counter market as RHHBY, operates through two main divisions covering diagnostics and pharmaceuticals. The company was founded in Basel in 1896 and now supplies medicines and diagnostic tools in more than 150 countries, with a stated focus on oncology, neurology, cardiovascular and metabolic disease, ophthalmology, infectious disease, and immunology.
Genentech operates as a fully owned subsidiary within the Roche Group structure, while Roche separately holds a majority stake in Chugai Pharmaceutical, a Japan-based innovator in therapeutic antibodies. That corporate structure allows Genentech to run U.S.-specific manufacturing and commercial strategy, including projects like the Genentech Hillsboro Manufacturing Expansion, while remaining integrated into Roche’s global research and manufacturing network.
Viewed against that backdrop, the Hillsboro project is one piece of a wider capital allocation pattern in which Roche has repeatedly directed investment toward U.S.-based device and biologics manufacturing rather than relying solely on facilities elsewhere in its global network. The Holly Springs and Hillsboro announcements, taken together, suggest the company is building redundancy into its device-based manufacturing capabilities across two separate U.S. regions.
What the Genentech Hillsboro Manufacturing Expansion Means for Patients and Investors
For investors and industry observers, the Genentech Hillsboro Manufacturing Expansion offers a signal about where Roche expects future demand for injectable and device-based therapies to concentrate. A $750 million capital commitment with a 2031 commercial start date reflects a long planning horizon typical of large-scale biologics fill-finish construction, which involves specialized cleanrooms, automated filling lines, and device assembly equipment that must pass regulatory qualification before commercial use.
For patients, the practical impact of the expansion will depend on which specific therapies are ultimately routed through the new Hillsboro lines, information Genentech has not yet detailed publicly. What the company has confirmed is that the facility is built to support a broad portfolio rather than a single product, giving Roche and Genentech flexibility to allocate device-filling capacity as new approvals and label expansions occur over the next several years.
The company said commercial operations are expected to begin in 2031, with site development and construction activity generating jobs in the interim. No additional financial terms, incentive packages, or state-level agreements were disclosed in the announcement, and figures beyond the $750 million investment total, the job creation estimates, and the 2031 timeline were not specified in the source release. As with prior Roche manufacturing announcements, additional operational detail is typically released closer to a facility’s commercial start date.
Hillsboro Facility Investment Snapshot
| Metric | Detail |
|---|---|
| Investing company | Genentech (Roche Group subsidiary) |
| Investment amount | Approximately $750 million |
| Facility location | Hillsboro, Oregon |
| Campus size | 75 acres |
| Facility type | Device fill-finish (injectable medicines and delivery devices) |
| Capacity change | Doubles size of existing facility |
| New manufacturing jobs | 250 (high-wage) |
| Construction jobs (development phase) | Approximately 200 |
| Expected commercial operations start | 2031 |
| Announcement date | 20 August 2026 |
| Announcement location | Basel, Switzerland |
